LATS1 and nonpapillary renal cell carcinoma: However, the percentage of the high LATS1 expression group was negatively associated with stage IV in ccRCC (stage I, 53.73%; stage IV; 12.94%), pRCC (stage I, 68.06%; stage IV; 0.69%), and chRCC (stage I, 39.39%; stage IV; 0%) (Fig. 5D).